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Abstract
Background: Currently the cytological examination of fine needle aspiration (FNA) biopsies is the standard
technique for the pre-operative differential diagnosis of thyroid nodules. However, the results may be non-
informative in ~20% of cases due to an inadequate sampling and the lack of highly specific, measurable
cytological criteria, therefore ancillary biomarkers that could aid in these cases are clearly needed. The aim of our
study was to evaluate the mRNA expression levels of 8 candidate marker genes as the diagnostic biomarkers for
the discrimination of benign and malignant thyroid nodules and to find a combination of biomarkers with the
highest diagnostic value.
Materials and methods: mRNA expression levels of eight candidate marker genes - BIRC5, CCND1, CDH1, CITED1,
DPP4, LGALS3, MET and TFF3 was measured by real-time RT-PCR in paired nodular and surrounding normal thyroid
tissue specimens of 105 consecutive patients undergoing thyroid surgery and compared between different types
of thyroid lesions.
Results: Significant differences in the mRNA expression levels between the normal and malignant thyroid tissues
and between benign and malignant nodules were found for BIRC5, CCND1, CITED1, DPP4, LGALS3, MET and TFF3,
but not CDH1. On a single gene basis, relative quantity (RQ) of LGALS3 had the highest diagnostic value for the
discrimination of malignant and benign thyroid nodules (AUC = 0.832, P < 0.0001 and 90.9% sensitivity and 65.6%
specificity at the optimal cut-off on ROC curve). The only two-marker set that outperformed LGALS3 was RQ sum of
LGALS3 and BIRC5 (AUC = 0.841, P < 0.0001). An application of multivariate logistic regression analysis resulted in
the generation of a multiplex biomarker model based on LGALS3, BIRC5, TFF3, CCND1, MET and CITED1 that had
considerably higher specificity than a single marker or two marker gene-based models (AUC = 0.895, P < 0.0001,
70.5% sensitivity and 93.4% specificity).
Conclusions: This study confirmed that mRNA expression levels of 7 out of 8 candidate genes analysed have a
diagnostic value for the distinction of benign and malignant thyroid nodules. The multiplex biomarker model
based on 6 genes outperformed a single marker or two marker-based models and warrants feasibility studies on
FNA biopsies and the validation in a larger cohort of patients.
Background
Thyroid nodules are a very common clinical finding -
the prevalence of palpable nodules ranges from 3 to 7%
in the general population but can be as high as 50%
based on ultrasonography or autopsy data [1]. Although
only less than 5% of the palpable nodules are malignant
lesions, thyroid cancers are the most common
malignancy of endocrine organs. According to European
Cancer Observatory data age-standardised incidence rate
was 3.1 cases and 8.8 cases per 100 000 in men and
women, respectively in Europe in 2008 and its incidence
rates have steadily increased over the recent decades
[2,3]. More than 95% of malignant lesions are derived
from thyroid follicular cells and are divided into papil-
lary and follicular carcinomas that differ mainly in the
mode of metastatic spread (lymphatic and haematogen-
ous spread, respectively) yet both are relatively indolent
tumours with 5-year survival rates > 90%, and
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any medium, provided the original work is properly cited.undifferentiated or anaplastic carcinoma that is a highly
aggressive and lethal cancer with 5-year survival rate
below 1-17% [4]. A minority of thyroid carcinomas are
derived from parafollicular cells (or C-cells) and are
referred to as medullary carcinomas with 5-year survival
rate of ~80% [4]. Benign nodules include hyperplasic
follicular adenomas, multinodular goiter, thyroiditis and
benign cysts [1].
The differential diagnosis of nodular thyroid disease is
based on cytological examination of fine needle aspira-
tion (FNA) biopsies, however the results may be non-
informative in ~20% of cases due to an inadequate sam-
pling and the lack of highly specific, measurable cytolo-
gical criteria [4,5]. Furthermore, the principal diagnostic
feature for follicular thyroid carcinomas (FTC) is capsu-
lar or vascular invasion and therefore it can not be reli-
ably distinguished from follicular adenomas by analysis
of FNA smears and the definite diagnosis relies on the
histological examination of the postoperative surgical
specimens [6]. Hence molecular biomarkers of malig-
nancy that could reliably discriminate between malig-
nant and benign nodules in the grey zone of thyroid
FNA and classify tumours into the histological subtypes
are clearly needed.
Gene expression profiling using cDNA microarrays or
serial analysis of gene expression (SAGE) has revealed
several hundreds of genes that are differentially
expressed between malignant and benign thyroid
nodules [7-9]. A number of them, including LGALS3,
MET etc have been shown to be functionally involved in
the carcinogenic process, have been validated by qRT-
PCR and confirmed at protein level by immunohisto-
chemistry [10-12]. However, several studies have
demonstrated that none of these genes individually has
sufficient sensitivity and specificity to be exploited as an
independent diagnostic biomarker [13,14] while using
very large panels of genes may not be practical. There-
fore the definition of minimal set of marker genes that
allows the correct classification of nodules is required in
order to develop a clinically applicable biomarker assay.
In the current study, we evaluated the diagnostic value
of 8 candidate marker genes - BIRC5, CCND1, CDH1,
CITED1, DPP4, LGALS3, MET and TFF3 by analysing
their mRNA expression levels in nodular and adjacent
relatively normal thyroid tissue specimens of 105 conse-
cutive patients with thyroid nodules who underwent
thyroidectomy, and developed a multiplex biomarker
model for the classification of the nodules.
Methods
Patients and tissue specimens
Paired specimens of thyroid nodules and surrounding
normal tissues were collected from 105 consecutive
patients undergoing total or partial thyroidectomy at
the Latvian Centre of Oncology and Pauls Stradi ņš
Clinical University Hospital during the period 2009-
2010. Tissue samples were macroscopically dissected
by histopathologist during the surgery and stored in
RNALater
® (Applied Biosystems, USA) at -20°C until
processing. Tissue sections were evaluated by experi-
enced pathologist and the diagnosis was established
according to standard histopathological criteria. Sixty
one of the nodules were diagnosed as follicular ade-
nomas (FA), 33 as papillary thyroid carcinomas
(PTC), 5 as medullar thyroid carcinomas (MTC), 3 as
anaplastic thyroid carcinomas (ATC) and 3 as follicu-
lar thyroid carcinomas (FTC). Selected clinical-patho-
logical data of the patient groups are provided in
Table 1. The specimens were collected after the
patients’ informed consent was obtained in accor-
dance with the regulations of Ethics Committee of
the University of Latvia Institute of Experimental and
Clinical Medicine.
Table 1 Clinical and pathological characteristics of the
patient groups
Characteristics Thyroid cancer
n=4 4
Benign nodule
n=6 1
Gender
Male 9 4
Female 35 57
Age at diagnosis
Mean ± SD 55 ± 17 54 ± 15
Median (range) 55 (24-83) 57 (25-83)
Family history of cancer 37 49
TSH level μIU/mL
Mean ± SD 2,31 ± 1,41 0,87 ± 0,74
Median (range) 1,32 (1,1-4,34) 0,75 (0,004-2,43)
US criteria
Hipoechogenic nodule 9 14
No Halozones 0 1
Irregular frontier
(non-homogenic)
61 4
Microcalcinates 4 9
Nodules > 3 cm 5 19
Central vascularization 3 3
Retrosternal 1 7
Swollen lymph nodes 2 0
No data 18 8
Histopathology
PTC 33
FTC 3
MTC 5
ATC 3
FA 61
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Tissue specimens were homogenised using the FastPrep-
24 instrument and Lysing Matrix D (MP Biomedicals,
USA) in 1 ml of Lysis solution
® (Ambion, USA) fol-
lowed by the extraction of total RNA using MirVana
®
(Ambion, USA) according to manufacturer’si n s t r u c -
tions. RNA extracted from tissue material was treated
with DNAse prior to cDNA synthesis (Ambion, USA)
a n dq u a n t i f i e db yN a n o D r o pN D - 1 0 0s p e c t r o p h o t -
ometer. cDNA was synthesized by random hexamer
priming from 4 μg of total RNA by using High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
USA) according to manufacturer’s instructions.
Quantitative RT-PCR
Quantitative RT-PCR (qPCR) reactions were performed
using 2 μl of 1:10 diluted cDNA reaction mixtures, ABSo-
lute Blue™ SYBR green Low ROX (Thermo Scientific,
USA) on ABI7500 sequence detection system (Applied
Biosystems, USA). Appropriate primer concentrations
were established by cDNA 4 log serial dilution curves to
ensure amplification efficiency over 95% and the specificity
of the amplification products were verified by the melting
curve analysis. Sequences of primers used in this study are
provided in Table 2. qPCR conditions were as follows:
hold for 15 minutes at 95°C, follow by two step PCR for
40 cycles of 95°C for 15 seconds, followed by 60°C for 1
minute. All reactions were performed in duplicates. To
choose the appropriate reference genes, a set of seven can-
didate reference genes (PGK1, PLA2, TUBA3, ACTB,
GAPDH, TBP, POLR2A) was tested for their mRNA
expression stability in 10 thyroid tissue samples from 5
patients (2 PTC, 3 FA, 5 normal) and the two most stable
genes (POLR2A and PGK1) were determined by using the
open-access software GeNorm Win3.4 (http://medgen.
ugent.be/~jvdesomp/genorm). Normalisation factor (NF)
for each cDNA sample was then calculated by using GeN-
orm Win3.4 based on PGK1 and POLR2A expression
level. Pooled cDNA from 10 thyroid tissue samples was
used as a reference sample and included in each experi-
ment to allow the comparison across multiple plates. The
expression level of each gene was determined relative to
its expression in the sample with the highest expression
(lowest Ct value). The analysis of relative gene expression
(RQ) data was performed using the 2
-ΔCT method and to
eliminate variations of cDNA quantity and quality the
data were normalised by using NF for each sample (RQ =
(2
-ΔCT)/NF).
Statistical analysis
A non-parametric Mann-Whitney U test was used to
compare the RQ values of each candidate gene between
Table 2 Primers used for qPCR
Name of the gene Sequence (5’->3 ’) Size of PCR product (bp) GenBank accession no.
Candidate genes
LGALS3 F CTGATTGTGCCTTATAACCTGC 100 NM_002306.3
LGALS3 R AAGCAATTCTGTTTGCATTGG
TFF3 F GTACGTGGGCCTGTCTGC 121 NM_003226.3
TFF3 R GATCCTGGAGTCAAAGCAGC
DPP4 F TGATGCTACAGCTGACAGTCG 164 NM_001935.3
DPP4 R CTGAGCTGTTTCCATATTCAGC
CITED1 F GCTCTGAAATGCCAACAACG 174 NM_001144886.1
CITED1 R TGGTTCCATTTGAGGCTACC
MET F TCTGCCTGCAATCTACAAGG 153 NM_001127500.1
MET R AAGGTGCAGCTCTCATTTCC
CDH1 F AGAAACAGGATGGCTGAAGG 199 NM_004360.3
CDH1 R AGCACCTTCCATGACAGACC
CCND1 F TGGTGAACAAGCTCAAGTGG 280 NM_053056.2
CCND1 R ATCACTCTGGAGAGGAAGCG
BIRC5 F CAGCCCTTTCTCAAGGACC 152 NM_001168.2
BIRC5 R AAGCAGAAGAAACACTGGGC
Hausekeeping genes
PGK1 F CTTAAGGTGCTCAACAACATGG 119 NM_000291.3
PGK1 R ACAGGCAAGGTAATCTTCACAC
POLR2A F GGGTCATCTTCCCAACTGGAG 164 NM_000937.4
POLR2A R CACCAGCTTCTTGCTCAATTCC
F - forward primer, R- reverse primer
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nant nodules; malignant nodules vs all normal tissue
specimens). The statistical significance was set at p <
0.05. The receiver operating characteristic (ROC) curve
was constructed and the area under the curve (AUC)
was calculated to evaluate the diagnostic performance of
each marker gene and biomarker model. Youden index
(J) was used to define cut-off points on the ROC curves
with the maximal sum of sensitivity and specificity. Mul-
tivariate logistic regression was used to examine associa-
tions between thyroid nodule histopathological status
and the gene expression data as described by Laxman B
et al [15]. The initial multivariate logistic regression
model included all individual genes and all combina-
tions. Stepwise backward elimination based likelihood
ratio test was used to drop out insignificant terms from
the initial model. The predicted probability for each
sample was calculated and used as input to generate
ROC curve. Leave one-out cross validation (LOOCV) as
described earlier was used to validate biomarkers and
combinations of them to eliminate overestimated values
[15]. The statistical analyses were performed with SPSS
17.0 (SPSS, USA), Genex (Multid, Sweden) and Graph-
PadPrism 5 (GraphPad, USA).
Results and discussion
Selection of candidate marker genes
The selection of candidate marker genes was based on
the functional involvement in various pathways contri-
buting to the acquisition of malignant phenotype and/
or previously reported differential expression in the
malignant and benign thyroid nodules. Cyclin D1
encoded by CCND1 is a crucial cell cycle regulator fre-
quently upregulated at protein level in PTC [16].
CITED1 encodes a cell cycle-dependent transcriptional
cofactor involved in TGF-beta and Bmp signalling that
may coordinate cellular differentiation and survival sig-
nals [17,18] and has been found to be overexpressed in
PTC by expression profiling using cDNA microarrays
[19], later confirmed as useful marker for FTC [6] and
validated at protein level by IHC [20]. Loss of expres-
sion or function of E-cadherin - a cell-cell adhesion
glycoprotein encoded by CDH1,h a sb e e nd e m o n -
strated to contribute to the progression of various can-
cers, including poorly differentiated thyroid cancers by
increasing proliferation, invasion and metastasis
[21,22]. Overexpression of dipeptidyl-peptidase 4
encoded by DPP4 in PTC has been demonstrated at
protein level by several groups [23-25], however the
mechanism how it may contribute to the development
or progression of thyroid malignancies remains
unknown. Survivin, an inhibitor of apoptosis encoded
by BIRC5, has been shown to be overexpressed in a
variety of cancers, including thyroid cancer, where it
contributes to uncontrolled cancer cell growth and
drug resistance [26,27]. Increased expression at the
mRNA and protein level of the receptor for hepatocyte
growth factor encoded by MET has been frequently
observed in PTC, follicular variant of PTC and at les-
ser degree in FTC where it promotes tumour progres-
sion by facilitating cell proliferation, survival,
migration, invasion, and metastasis [28-30]. However,
to our knowledge, so far the diagnostic value of CDH1,
DPP4, BIRC5 and MET mRNA levels has not been
established. Galectin 3 encoded by LGALS3 plays an
important role in cell-to-cell adhesion, cell-to-matrix
interactions and the regulation of apoptosis and prolif-
eration, and its overexpression correlates with thyroid
cancer aggressiveness and metastasis [31,32]. Although
TFF3 mRNA has been shown to be overexpressed in
several solid cancers, such as hepatocellular carcinoma,
colon and prostate cancer, and suggested to contribute
the malignant behaviour and metastasis [33-36], SAGE
analysis of thyroid follicular adenomas and carcinomas
demonstrated that it is downregulated in FTC [37] and
later this finding was confirmed in PTC and ATC by
other researchers [14,38], thus validating TFF3 down-
regulation as a universal marker of cancers derived
from thyroid follicular cells. It encodes a small
secreted protein - trefoil factor 3, which is abundantly
expressed at mucosal surfaces and promotes regenera-
tion and repair. Interestingly, recent reports demon-
strate that both galectin-3 and TFF3 are involved in
ciliogenesis, epithelial cell differentiation and polarity
[39,40], thus suggesting a y e tu n e x p l o r e dr o l eo ft h e
deregulation of these processes in the development of
thyroid cancer.
mRNA expression analysis and the diagnostic
performance of individual marker genes
mRNA expression analysis of the selected marker genes
by RT-qPCR revealed statistically significant differences
both between the normal and malignant thyroid tissues
and between benign and malignant nodules for all genes
except CDH1, thus further supporting their role the
development and/or progression of thyroid cancer.
LGALS3, DPP4, MET, CITED1, CCND1 and BIRC5
were found to be significantly upregulated while TFF3
was downregulated in the malignant tissues (Table 3
and Figure 1). At first, all the genes were tested by ROC
curve analysis as individual biomarkers, which demon-
strated that LGALS3 have the highest value for discrimi-
nating malignant from benign nodules in our sample set
(AUC = 0.832, P < 0.0001). The cut-off of LGALS3
expression level (RQ) that discriminates benign and
malignant nodules with the highest accuracy (sensitivity
90.9%, specificity 65.6%) was determined to be 0.019.
The sensitivity for the detection of various subtypes of
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specimens were classified correctly thus confirming that
LGALS3 may serve as a universal diagnostic marker of
the thyroid malignancies. However, 22 of 61 benign
nodules were misclassified using this cut-off. As the
ROC curve was constructed using all the samples, it
may lead to overestimation of the AUC, therefore we
next used LOOCV to validate it. The AUC for LOOCV
LGALS3 model dropped to 0.783, nevertheless it still
outperformed the other marker genes. Although pre-
viously the diagnostic utility of LGALS3 mRNA expres-
sion level has been questioned, our data show that the
diagnostic accuracy of mRNA quantification is compar-
able to that reported in immunohistochemical studies
[32]. The next marker genes with the highest diagnostic
v a l u ei no u rs a m p l es e tw e r eTFF3 (AUC = 0.696, P =
0.001) and DPP4 (AUC = 0.695 and P = 0.001). The
optimal RQ cut-off for TFF3 was determined to be
0.011 allowing the discrimination between benign and
malignant nodules with sensitivity 54.6% and specificity
90.2%, while for DPP4 the cut-off was 0.027 with sensi-
tivity 45.6% and specificity 88.5%.
Interestingly, in 3 PTC and 2 MTC cases none or only
one of the genes analysed were differentially expressed
between cancerous and relatively normal tissues in spe-
cimens and they were consistently misclassified as
benign nodules. These specimens are likely to represent
a distinct molecular subtype of thyroid cancer, in which
different molecular pathways predominate and therefore
next these samples will be subjected to gene expression
profiling using cDNA microarrays.
Development of multiplex biomarker model
To determine if a combination of markers could out-
perform the single biomarkers we systematically
searched for two-marker ratios or two-marker sums,
and determined their diagnostic performance by ROC
curve analysis. In total, 27 two-marker combinations
were evaluated, however only one of them - LGALS3
and BIRC5 RQ sum showed higher AUC for discrimi-
nating benign and malignant nodules than the best
individual marker gene (AUC = 0.841, P < 0.0001 and
AUC = 0.809, P < 0.0001 for the LOOCV model) (Fig-
ure 2A,B). At the best cut-off, the sensitivity was 79.5%
and specificity was 78.7%. As shown in Figure 2D, this
two-gene combination could detect all FTC and ATC
cases but failed to detect 7 of 33 PTCs (21%) and 2 of
5 MTCs (40%) thus suggesting it may have lower value
for diagnosing MTC, however this finding should be
verified in larger cohort of patients. So far, the best
reported two-marker set is TFF3/LGALS3 ratio that
has been shown to discriminate follicular carcinomas
from follicular adenomas with 72.4% sensitivity and
83.3% specificity (or 80% and 91.5%, when the patholo-
gically questionable cases were excluded) [41]. In our
sample set it showed similar performance (AUC =
0.758, P < 0.0001, sensitivity 72.7%, specificity 85.3%).
However, although it could improve the specificity, the
overall accuracy of TFF3/LGALS3 ratio was lower than
that of LGALS3 alone. Moreover, as TFF3 is downre-
gulated in cancer cells, the development of assay that
is based on the measurement of its expression level in
FNA biopsies consisting of a mixture of different cell
types is technically more challenging than the assay
Table 3 Relative expression values and the diagnostic performance of the marker genes
Gene, protein name RQ values - Mean ± SEM Mann-Whitney U test - p-values ROC curve - AUC
(Asimptotic significance)
Normal Benign Malignant Normal vs
Malignant
Benign vs
Malignant
Normal vs
Malignant
Benign vs
Malignant
LGALS3, Galectin-3 0.068 ±
0.013
0.035
± 0.007
0.248 ±
0.067
2.2 × 10
-5 1×1 0
-8 0.715
(< 0.0001)
0.832
(< 0.0001)
TFF3, trefoil factor 3 0.115
± 0.011
0.066 ±
0.007
0.037 ±
0.008
4.1 × 10
-8 0.0003 0.782
(< 0.0001)
0.696
(0.001)
DPP4, Dipeptidyl peptidase-4 0.011
± 0.002
0.0146
± 0.003
0.066 ±
0.016
0.0001 0.0004 0.693
(< 0.0001)
0.695
(0.001)
MET, hepatocyte growth factor
receptor
0.048
± 0.005
0.033 ±
0.004
0.110 ±
0.021
0.01 0.0005 0.610
(0.037)
0.689
(0.001)
CITED1, Cbp/p300-interacting
transactivator 1
0.010
± 0.002
0.021 ±
0.008
0.161 ±
0.048
0.001 0.001 0.654
(0.003)
0.67
(0.003)
CCND1, Cyclin D1 0.037
± 0.004
0.036 ±
0.007
0.084 ±
0.017
0.002 0.001 0.647
(0.005)
0.67
(0.003)
BIRC5, Survivin 0.025
± 0.011
0.009 ±
0.002
0.045 ±
0.018
0.0001 0.001 0.694
(< 0.0001)
0.668
(0.003)
CDH1,E-cadherin 0.171
± 0.013
0.117 ±
0.009
0.158 ±
0.018
0.2 0.06 0.464
(0.497)
0.525
(0.697)
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BIRC5 RQ sum seems to be more suitable for the clin-
ical application.
Next, we applied a multivariate logistic regression ana-
lysis to define a multiple marker set that could improve
the diagnostic performance over single markers or two-
marker combinations. Similar approach has been pre-
viously successfully used by Laxman B et al to develop a
multiplex biomarker model for the detection of prostate
cancer [15]. This resulted in the multiplex model that
included LGALS3 and BIRC5 RQ sum, TFF3 and
LGALS3 RQ ratio, TFF3 and CCND1 RQ ratio, ratio
between TFF3 RQ and MET, CITED1 RQ sum, ratio
between TFF3 RQ and MET, BIRC5 RQ sum and ratio
between TFF3 RQ and CCND1, BIRC5 RQ sum.
Although the overall performance of the model (AUC =
0.895, P < 0.0001 and AUC = 0.823, P < 0.0001 for the
LOOCV model) was only slightly improved over
LGALS3 alone or LGALS3 and BIRC5 RQ sum, at the
best cut-off, this model shows 70.5% sensitivity and
93.4% specificity and as shown in Figure 2A it has con-
siderably higher specificity that is a clear requirement
for the development of clinically applicable biomarker
assay.
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Figure 1 Median mRNA expression levels of the candidate marker genes in groups of 61 benign and 44 malignant thyroid nodules
represented by box plots. The relative quantity (RQ) of each marker gene in each sample was calculated using 2
-ΔCT method and normalised
by using normalisation factor obtained by analysis of the two most stable reference genes (RQ = (2
-ΔCT)/NF). Boxes represent the 25
th and 75
th
percentiles; whiskers represent the minimum and maximum values. Statistical significance was calculated using Mann-Whitney U test.
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LGALS3 0.832 0.041 <0.0001 90.9% 65.6% 0.752 0.913
LGALS3 LOOCV 0.783 0.047 <0.0001 70.5% 78.7% 0.691 0.875
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Figure 2 The diagnostic performance of the best individual marker, two-marker set and multiplex biomarker model. A and B represents
ROC curves of the best individual marker, two-marker set and multiplex model and their LOOCV ROC curves, respectively. C, D, E - Scatter dot
plot of LGALS3 RQ, LGALS3 and BIRC5 RQ sum and Multiplex model with the best cut off shows how many benign nodules, malignant nodules
and thyroid cancer subtypes are misclassified. In table are the best individual marker, two-marker set and multiplex biomarker model and their
LOOCV model ROC curve AUC data and sensitivity and specificity at the best cut-off point.
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genes to the multiplex model that would enable detect-
ing other molecular subtypes of thyroid cancer, testing
the feasibility of the biomarker assay in FNA biopsies
and validating the assay in a large multicenter clinical
trial.
Conclusions
mRNA expression analysis of 8 candidate marker genes
- BIRC5, CCND1, CDH1, CITED1, DPP4, LGALS3,
MET and TFF3 in paired nodular and relatively normal
thyroid tissue specimens of 105 consecutive patients
undergoing thyroid surgery demonstrated that all of
them except CDH1 are differentially expressed between
the normal and malignant thyroid tissues and between
benign and malignant nodules, and LGALS3 had the
highest diagnostic value for the discrimination of
malignant and benign thyroid nodules on a single gene
basis. An application of multiv a r i a t el o g i s t i cr e g r e s s i o n
analysis resulted in the generation of a multiplex bio-
marker model based on LGALS3, BIRC5, TFF3,
CCND1, MET and CITED1 that outperformed a single
marker or two marker gene-based models by increas-
ing the specificity, which is a prerequisite for the
development of clinically applicable biomarker assay.
The next step will be to test the feasibility of this assay
on FNA biopsies and to validate it in a larger cohort
of patients.
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